Cerebral Ischemia, Inhaled Nitric Oxide, SAH, Vasospasm
Conditions
Brief summary
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare but severe subtype of stroke with high mortality and morbidity. Besides rebleeding, delayed cerebral ischaemia and cerebral vasospasm (CVS) are thought to be major reasons for the poor outcome in survivors of aSAH. Despite advances in the detection and treatment of CVS 20-40% of CVS patients experience cerebral Ischaemia. Experimental animal studies for ischaemic stroke, traumatic brain injury, and SAH showed that inhaled nitric oxide (iNO) selectively dilates cerebral arteries and arterioles in hypoperfused brain tissue. The investigators therefore performed this prospective pilot study to evaluate the effects of iNO on cerebral perfusion in patients with refractory vasospasm after aSAH.
Detailed description
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare but severe subtype of stroke with high mortality and morbidity. Besides rebleeding, delayed cerebral ischaemia and cerebral vasospasm (CVS) are thought to be major reasons for the poor outcome in survivors of aSAH. CVS, thought to be caused by blood breakdown products, peak in the second week after hemorrhage and affect up 88% of patients with severe aSAH. Despite advances in the detection and treatment of CVS there is no established therapy and up 40% of patients experience cerebral ischemia. In symptomatic vasospasm and cerebral hypoperfusion various treatments like induced hypertension, angioplasty and intraarterial vasodilators are used as rescue therapies. Yet, their effect is not proven. In recent experimental studies, inhaled nitric oxide (iNO) has been shown to induce a selective dilation of cerebral arteries and arterioles in hypoperfused brain tissue \[8, 9\]. After experimental SAH in mice, iNO significantly reduced the number and severity of SAH-induced spasms of cerebral microvessels, thereby improving cerebral perfusion. Inhaled NO has regulatory approval in man by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of several pulmonary pathologies. At first the efficacy of iNO was thought to be limited to the lungs but, based on the results of the experimental studies the investigators hypothesised that iNO may relieve CVS and improve cerebral perfusion in patients with aSAH. The investigators performed this prospective trial to evaluate the effect of iNO on cerebral perfusion in patients with severe refractory CVS. Only patients with refractory CVS after maximum conservative treatment were included. Inhaled NO was administered to a maximum dose of 40ppm. The effect was assessed by digital subtraction angiography (DSA), tissue oxygen partial pressure (PtiO2), transcranial Doppler (TCD), and CT perfusion (CTP) imaging. Patiente outcome is assessed at 12 weeks an 6 months after hemorrhage and included NIHSS, Mini Mental State (MMS) test, and modified Rankin Scale (mRS).
Interventions
DRUGInhaled nitric oxide
Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
Sponsors
Insel Gruppe AG, University Hospital Bern
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Administration of iNO in SAH patients with severe vasospasm
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* aSAH of all severities * Aneurysm treated by either surgical clipping or endovascular coiling * Age between 18 - 80 years * Proven CVS * Cerebral hypoperfusion and neurological deficit despite treatment (oral nimodipine, induced hypertension, hypervolaemia, central venous pressure \> 6 mmHg) * A negative pregnancy test in women * Signed informed consent from the next of kin and an independent physician
Exclusion criteria
* Unsecured aneurysm * Cerebral infarction on imaging in the downstream brain parenchyma of spastic vessel * Cerebral herniation * Intracranial pressure \> 25 mmHg * Pregnancy * Mean arterial pressure ≤ 90 mmHg despite catecholamines
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of severe vasospasm in CT perfusion | Day 2 | A reduction in the number of Region of interest with impaired perfusion (MTT \> 6·5 s) |
| Improvement of severe vasospasm in digital subtraction angiography | Up to 5 days | \> 10% increase in diameter of the vasospastic target vessel compared to baseline |
| Improvement of severe vasospasm in tissue oxygen partial pressure (PtiO2) | Up to 5 days | An increase of more than 5 mmHg with constant fraction of inspired oxygen (FiO2) |
| Improvement of severe vasospasm in transcranial Doppler | Up to 5 days | A decrease of more than 30 cm/s |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial pressure | Up to 5 days | Intracranial pressure using an external ventricular drain catheter |
| Assessment of ischaemic events by CT Scan | 12 weeks after SAH | — |
Countries
Switzerland
Outcome results
None listed